• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Xenon Pharmaceuticals Inc (NQ: XENE )

    40.30 +0.22 (+0.55%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Aug 29, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 183,370
    Open 40.06
    Bid (Size) 16.36 (1)
    Ask (Size) 64.20 (1)
    Prev. Close 40.08
    Today's Range 39.53 - 41.11
    52wk Range 27.98 - 50.99
    Shares Outstanding 63,562,303
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024
    XENE stock results show that Xenon Pharmaceuticals missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    -10.26%
    -10.26%
    1 Month
    -5.80%
    -5.80%
    3 Month
    +3.23%
    +3.23%
    6 Month
    -14.62%
    -14.62%
    1 Year
    +3.65%
    +3.65%

    More News

    Read More
    Xenon Reports Q2 2024 Financial Results and Business Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon to Report Q2 2024 Financial Results on August 8, 2024
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Earnings Scheduled For February 29, 2024
    Via Benzinga
    Earnings Outlook For Xenon Pharmaceuticals
    Via Benzinga
    Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024
    Via InvestorPlace
    Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
    Via InvestorPlace
    This Analyst Is Bullish On Biohaven's Approach in Neuro-Psych Space
    Via Benzinga
    Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    From Xenon Pharmaceuticals Inc.
    Via GlobeNewswire
    Bristol Myers Squibb’s big buys: $18.1 billion in 2 biotech deals
    Via MarketBeat
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.